- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: March 2018
- Public Summary Document (PSD) March 2018 PBAC Meeting - PDF
- Public Summary Document (PSD) March 2018 PBAC Meeting - Word
Pembrolizumab (nsclc) – March 2018
Pembrolizumab (NSCLC): Powder for injection 50 mg, solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda®
Last updated
13 July 2018